Bill Proposing an Appropriation into the Arizona Health Innovation Trust Fund Receives Unanimous Support in the Senate Health and Human Services Committee

SB1019: appropriation; health innovation trust fund received its first hearing in Arizona’s Senate Health and Human Services Committee on January 16, 2024.  As currently written, SB1019 appropriates $5M to the Arizona Health Innovation Trust Fund, and declares that it is the Legislature’s intent that the Fund, consisting of monies appropriated by the Legislature, gifts or grants donated or given to the Fund and earnings from the Fund, steadily grow to ultimately maintain a permanent endowment balance of at least $200 million. 

SB1019 received a unanimous do pass recommendation.  It now is eligible for consideration by the Senate Appropriations Committee.Continue reading

C-Path to Lead New Task Force Aimed at Accelerating Drug Development for Mitochondrial and Inherited Metabolic Diseases

TUCSON, Ariz., January 11, 2024 — Critical Path Institute (C-Path) today announced the launch of a task force focused on accelerating drug development for mitochondrial and inherited metabolic diseases. The task force will lay the groundwork for specific solutions, offering valuable insights that aim to contribute to regulatory decision-making.Continue reading

An Interview with AZBio President and CEO on Life Sciences M&A in Arizona

Recently, PULSE had a conversation with Joan Koerber-Walker, president and CEO of AZBio, which recently celebrated 20 years of supporting the growth of Arizona’s life science industry. Joan, who has led AZBio since 2011, has a vested interest in making Arizona a place where bioscience organizations can thrive and find success, while supporting economic growth at the local and state level. PULSE asked Joan for her perspective on how mergers and acquisitions (M&A) have impacted and benefited Arizona’s economic outlook and contributions to the state.

Continue reading

Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report

FRIENDSWOOD, Texas–(BUSINESS WIRE)– Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its Chief Operating Officer, Kristen Oelschlager, has been named to The Healthcare Technology Report’s Top 25 Women Leaders in Biotechnology of 2023. The honorees “stand as a driving force, ensuring diverse perspectives on scientific breakthroughs and groundbreaking therapies,” according to the publication. “Their achievements serve as inspiration, paving the way for future generations of women leaders in biotech to continue shaping the future of healthcare.”Continue reading